Souhaitez-vous accéder aux communiqués récents ?

EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent...

London, UK – 19th October 2023. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...

EvolveImmune to Highlight New Data on Precision Medicine Potential of Evolve Platform and Lead Development Programs in Presentations at SITC 2023

— Accomplished clinical leader with significant expertise in hematology/oncology drug development and a track record of advancing multiple modalities of cancer therapeutics — SAN MATEO, Calif., Oct. ...

GT Apeiron Therapeutics announces development candidate nomination of GTA182, a brain penetrant MTA-cooperative PRMT5 inhibitor

- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors   ...

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of...

EDEN PRAIRIE, Minn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Elucent Medical, a pioneering medical device company specializing in developing innovative solutions for sensitive cancer screening techniques...

Klinische Programm-Updates mit neuen Daten für CAR-T- und ex-vivo T-Zelltherapiekandidaten, einen innovativen ADC-Kandidaten, einen off-the-shelf Krebsimpfstoffkandidaten der FixVac-Plattform und...